Literature DB >> 16681683

Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index.

P Jalava1, T Kuopio, L Juntti-Patinen, T Kotkansalo, P Kronqvist, Y Collan.   

Abstract

AIMS: Counting mitotic figures is considered to be a reliable prognosticator, but evaluation of Ki67 immunohistochemistry has become more popular in evaluating proliferation. Our previous studies suggested an occasional discrepancy between mitotic figures and Ki67 fraction. The aim of this study was to investigate this more closely and also to study the associations between bcl-2 and p53 expression and proliferation. METHODS AND
RESULTS: Two hundred and sixty-five infiltrating breast carcinomas were immunostained for Ki67, p53 and bcl-2. The standardized mitotic index (SMI) was determined. Four proliferation groups were based on Ki67 positivity fraction and SMI at optimal cut-off points. Cox's multivariate model was used to test the power of the prognosticators. SMI and nodal status were the most powerful individual prognosticators. Ki67 was an independent prognosticator if nodal status, tumour size, age and histological grade were included in the analysis but not if analysed with SMI. The group with low SMI and low Ki67 fraction had the best prognosis. Groups with high SMI had the poorest prognosis. The group with low SMI and high Ki67 fraction had a favourable prognosis. Bcl-2 negativity and p53 positivity correlated with proliferation.
CONCLUSIONS: We have found a 'wrong positive' Ki67 group with favourable prognosis. SMI cannot be replaced by Ki67 because of the danger of misclassification of some patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681683     DOI: 10.1111/j.1365-2559.2006.02402.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  56 in total

1.  Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer.

Authors:  Min Ying; Yingjian He; Meng Qi; Bin Dong; Aiping Lu; Jinfeng Li; Yuntao Xie; Tianfeng Wang; Benyao Lin; Tao Ouyang
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

2.  Cytoplasmic expression of the JM403 antigen GlcA-GlcNH3+ on heparan sulfate glycosaminoglycan in mammary carcinomas--a novel proliferative biomarker for breast cancers with high malignancy.

Authors:  Masahiro Fujii; Akiko Yusa; Yukihiro Yokoyama; Toshio Kokuryo; Nobuyuki Tsunoda; Koji Oda; Masato Nagino; Tsuyoshi Ishimaru; Yoshie Shimoyama; Hirotoshi Utsunomiya; Hiroji Iwata; Yoshiko Itoh; Johbu Itoh; Reiji Kannagi; Mamoru Kyogashima
Journal:  Glycoconj J       Date:  2010-11-03       Impact factor: 2.916

3.  The use of digital images improves reproducibility of the ki-67 labeling index as a proliferation marker in breast cancer.

Authors:  András Vörös; Erika Csörgő; Bence Kővári; Péter Lázár; Gyöngyi Kelemen; Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2013-11-08       Impact factor: 3.201

4.  miR-26a is required for skeletal muscle differentiation and regeneration in mice.

Authors:  Bijan K Dey; Jeffrey Gagan; Zhen Yan; Anindya Dutta
Journal:  Genes Dev       Date:  2012-10-01       Impact factor: 11.361

5.  Engendering allograft ignorance in a mouse model of allogeneic skin transplantation to the distal hind limb.

Authors:  Shailesh Agarwal; Shawn Loder; Sherri Wood; Paul S Cederna; D Keith Bishop; Stewart C Wang; Benjamin Levi
Journal:  Ann Surg       Date:  2015-03       Impact factor: 12.969

Review 6.  AMP-activated protein kinase and energy balance in breast cancer.

Authors:  Hong Zhao; Yelda C Orhan; Xiaoming Zha; Ecem Esencan; Robert T Chatterton; Serdar E Bulun
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

7.  Down-regulation of claudin-3 is associated with proliferative potential in early gastric cancers.

Authors:  Takuya Okugawa; Tadayuki Oshima; Xin Chen; Kazutoshi Hori; Toshihiko Tomita; Hirokazu Fukui; Jiro Watari; Takayuki Matsumoto; Hiroto Miwa
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

8.  Molecular alterations in key-regulator genes among patients with T4 breast carcinoma.

Authors:  Bruno Massidda; Mariacristina Sini; Mario Budroni; Francesco Atzori; Mariacristina Deidda; Valeria Pusceddu; Mariateresa Perra; Paola Sirigu; Antonio Cossu; Grazia Palomba; Mariateresa Ionta; Giuseppe Palmieri
Journal:  BMC Cancer       Date:  2010-08-24       Impact factor: 4.430

9.  Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types.

Authors:  M H W Starmans; B Krishnapuram; H Steck; H Horlings; D S A Nuyten; M J van de Vijver; R Seigneuric; F M Buffa; A L Harris; B G Wouters; P Lambin
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

10.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.